
The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
‘Bootle Blast’ combines therapy and video games. It has been used with children and youth with musculoskeletal disabilities in clinics and homes. Preliminary research supports Bootle Blast’s ability to engage players and support physical outcomes. Informal testing suggests it may also appeal to older adults. This study will test Bootle Blast’s feasibility with people with dementia. Pairs of people with dementia and their caregivers (n=10) will play Bootle Blast at home for 2 weeks. Data will include video recordings, surveys, balance tests, safety and adherence tracking, and interviews. This study aims to inform a more accessible version of Bootle Blast.
People with Dementia
• Live in Ontario, Canada (within a two-hour drive from Toronto, Ontario)
• Speak and understand English
• Agree to be video and audio recorded as part of the study
• Be able to stand and walk, with or without an assistive device (e.g., a walker)
• Have the capacity to provide independent, informed consent
Caregivers
• Live in Ontario, Canada (within a two-hour drive from Toronto, Ontario)
• Speak and understand English
• Agree to be video and audio recorded as part of the study
By understanding the perspectives of various stakeholders involved in dementia care within Ontario health teams, we aim to enhance the quality of life for individuals living with dementia in Ontario.
You are eligible to participate if you or your loved one is living with dementia and would like to share your experience so that we can act to improve the quality of care for individuals living with dementia in Ontario.
This study looks at how an at-home nature-based virtual reality (VR) program may help people living with Alzheimer’s disease manage behavioural and psychological symptoms of dementia (BPSD), such as depression. Caregivers/study partners will have the option of taking part in the study and providing feedback regarding the VR intervention. This project will explore how VR can be used as a non-pharmacological approach to prolong aging in place for individuals with BPSD, as BPSD contributes to rates of institutionalization. This will take place completely remotely, in your own home.
AD-D Participant Inclusion Criteria:
1) Clinical diagnosis of mild to early-moderate stage AD (including mixed dementia with AD) using the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. Criteria (29)
2) Age of 50 years or older
3) Medical stability to participate in the trial
4) Patient Health Questionnaire score 5-14
5) Investigator judgement on whether the participant is comfortable with technology
6) Access to WiFi and a smart device for connecting on WebEx and downloading the Fitbit and Muse applications
7) Have someone available to be present during all sessions
Caregiver Inclusion Criteria:
1) 18 years of age or older
2) Available to be present for all sessions
3) Ability to provide consent
4) Access to a smart device
Caregiver Exclusion Criteria:
1) Under 18 years of age
Seeking individuals with mild, early-stage dementia ages 65+ to explore how they access daily information like weather forecasts and newspapers. The study aims to improve information accessibility for the dementia community. Participation involves a 60-90 minute session (in-person or via Zoom with caregiver) observing information access behaviors. Findings will guide strategies for making information more comprehensible and accessible. Participants will receive $50 for their time. This study is approved by York University’s ethics committee (#2024-176). For details, contact Dr. Somang Nam at [email protected].
Individuals diagnosed with mild, early-stage dementia.
Caregivers may participate to support individuals meeting the above criteria.
Participants must be able to engage in a 60-90 minute session, either in person or via Zoom.
We are interested in how the brain changes in aging and with dementia. With this study, we will investigate how the brain senses and interprets sights and sounds. We are particularly interested in how listening to music, especially familiar music, evokes emotions and activates vivid memories. Learning how the brain processes music will help us understand why music therapy is such an effective tool for those with Alzheimer’s. We also aim to understand how the brain combines sights and sounds. This is an important part of how we navigate complex everyday situations, such as walking down a busy street. Alzheimer’s disease interferes with the brain’s ability to combine information from different senses, which could cause challenges in daily living.
You are eligible to participate in this study if you are:
You will not be eligible to participate in the study if you:
The Communication Bridge 3 Study is focused on helping adults with mild to moderate Primary Progressive Aphasia (PPA), a condition that affects language abilities due to neurodegenerative diseases. The study aims to improve functional communication and life participation by providing structured language and communication support remotely through video conferencing.
Participants work with speech-language pathologists to practice communication techniques and learn strategies to address daily communication challenges. The study involves a series of therapy sessions, assessments, and follow-up evaluations to measure changes in communication and participation over time. By tracking participants' progress, the study hopes to identify effective approaches for enhancing quality of life for those living with PPA and their care partners.
You are eligible to participate if you speak English as a primary language, a confirmed diagnosis of PPA in mild to moderate impairment stage, a communication partner that is willing to participate, and sufficient internet connection.
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Male or female participants aged 50 to 80 years of age
MCI or Mild AD at Screening
Must have a study partner
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Male or female participants aged 55 to 90 years of age
MCI or Mild AD at Screening
Must have a study partner
This study examines how people with dementia or MCI perform household tasks, focusing on when they seek support, and which prompts help them complete tasks. The findings will help develop technologies to assist them in completing tasks more independently and safely.
You are eligible to participate if you are:
• An older adult aged 60-85
• Fluent in English
• Diagnosed with dementia or MCI
• Enrolled in outpatient care
Follow us: